PL3.F TuHURA Biosciences, Inc.
- Market cap
- EUR 84.8M
- P/E
- -
- P/B
- 5.65x
- ROE
- -181.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PL3.F undervalued?
Graham numberThe Graham number of TuHURA Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TuHURA Biosciences, Inc. fundamental analysis
No fundamental analysis for TuHURA Biosciences, Inc. yet.
TuHURA Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta recep…
Full company profileTuHURA Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TuHURA Biosciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.11M | -9.72M | -13.2M | -17.2M | -27.3M | -32.6M |
| EBITDA | - | -8.99M | -29.1M | -17.4M | -29.4M | -32.4M |
| Net Income | -7.02M | -9.37M | -29.3M | -21.7M | -30.1M | -33.5M |
| EPS | -0.17 | -0.22 | -0.70 | -0.51 | -0.51 | -0.53 |
| Balance Sheet | ||||||
| Total Assets | 6.40M | 15.2M | 4.36M | 20.0M | 27.4M | 31.7M |
| Total Liabilities | 7.15M | 2.89M | 5.92M | 5.37M | 6.42M | 13.2M |
| Shareholders' Equity | -748K | 12.3M | -1.56M | 14.6M | 20.9M | 18.5M |
| Cash & Short-term Investments | 5.55M | 14.3M | 3.67M | 12.7M | 3.62M | 996K |
| Cash Flow | ||||||
| Operating Cash Flow | -6.56M | -7.51M | -12.0M | -14.7M | -27.6M | -26.1M |
| Capital Expenditure | 3.28K | 36.3K | 79.2K | 57.9K | 76.1K | 372K |
| Free Cash Flow | -6.57M | -7.54M | -12.0M | -14.8M | -27.7M | -26.5M |
| Ratios | ||||||
| ROE | - | -76.1% | - | -148.6% | -143.6% | -181.2% |
| ROA | -109.6% | -61.6% | -672.1% | -108.6% | -109.9% | -105.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
TuHURA Biosciences, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.36K | 0.00 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns TuHURA Biosciences, Inc.
- Insiders 34.62%
- Institutions 14.18%
- Public & others 51.20%
- Shares outstanding 63.7M
- Free float 39.7M
TuHURA Biosciences, Inc. company profile
- Company name
- TuHURA Biosciences, Inc.
- Ticker
- PL3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- 10500 University Center Drive, Tampa, FL, United States, 33612
- Phone
- 813 875 6600
- Website
- tuhurabio.com
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
TuHURA Biosciences, Inc. management
6- Dr. James A. Bianco M.D.President, CEO & Director · born 1957
- Mr. Dan Dearborn CPAExecutive VP of Finance & CFO · born 1967
- Mr. Michael LawmanCo-Founder
- Ms. Patricia LawmanCo-Founder
- Mr. Michael KrsulichHead of Quality Assurance
- Ms. Amanda GarofaloSenior Vice President of Clinical Operations